InflaRx Cuts Costs 30% and Advances Izicopan HS Phase 2b Plans After Positive Phase 2a Data
InflaRx presented positive Phase 2a hidradenitis suppurativa data for izicopan, showing reductions in draining tunnels and pain within four weeks across multiple doses in roughly 200 patients without hepatotoxicity signals. The company cut costs by 30% after halting vilobelimab Phase 3, and plans a Phase 2b trial design this spring.
1. Phase 2a Basket Study Shows Early HS and CSU Signals
InflaRx reported that its oral C5aR antagonist izicopan achieved positive proof-of-concept in a Phase 2a basket study in hidradenitis suppurativa and chronic spontaneous urticaria, with around 200 patients across multiple doses showing notable reductions in draining tunnels and pain after four weeks and no hepatotoxicity signals.
2. Planning Regulator-Engaged Phase 2b Design
The company plans to finalize its Phase 2b trial design this spring, leveraging new long-term toxicology data from a nine-month non-human primate study and engaging with regulators on dose selection and endpoints to support a robust efficacy assessment.
3. Cost Base Reduction and Strategic Refocus
After stopping its vilobelimab Phase 3 program and exiting a niche COVID opportunity, InflaRx cut its cost base by approximately 30% and will host a Capital Markets Day to discuss strategic options, additional indications and resource allocation.